GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Obalon Therapeutics Inc (NAS:OBLN) » Definitions » 5-Year Yield-on-Cost %

Obalon Therapeutics (Obalon Therapeutics) 5-Year Yield-on-Cost % : 0.00 (As of May. 08, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Obalon Therapeutics 5-Year Yield-on-Cost %?

Obalon Therapeutics's yield on cost for the quarter that ended in Mar. 2021 was 0.00.


The historical rank and industry rank for Obalon Therapeutics's 5-Year Yield-on-Cost % or its related term are showing as below:



OBLN's 5-Year Yield-on-Cost % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 2.2
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Obalon Therapeutics's 5-Year Yield-on-Cost %

For the Medical Devices subindustry, Obalon Therapeutics's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Obalon Therapeutics's 5-Year Yield-on-Cost % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Obalon Therapeutics's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Obalon Therapeutics's 5-Year Yield-on-Cost % falls into.



Obalon Therapeutics 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Obalon Therapeutics is calculated as

Yield-on-Cost=Dividend Yield %*(1+Dividend Growth Rate)^5

Obalon Therapeutics  (NAS:OBLN) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.


Obalon Therapeutics 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Obalon Therapeutics's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.


Obalon Therapeutics (Obalon Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
5421 Avenida Encinas, Suite F, Carlsbad, CA, USA, 92008
Obalon Therapeutics Inc is a medical device company that focuses on developing and commercializing medical devices to treat obese and overweight people by facilitating weight loss. Its product includes Obalon Balloon System. Geographically, it derives all of its revenue from the United States.
Executives
Raymond V Dittamore director P O BOX 2050, GLENWOOD SPRINGS CO 81602
William J. Plovanic director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Sharon Stevenson director C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ECINAS, SUITE F, CARLSBAD CA 92008
Douglas Fisher director 587 PATROL RD, WOODSIDE CA 94062
Lesley H Howe director
Kim P. Kamdar director C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542
Andrew P Rasdal director, officer: President, CEO & Exec Chairman C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Nooshin Hussainy officer: Chief Financial Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Mark Brister officer: Chief Technology Officer C/O DEXCOM, INC., 5555 OBERLIN DRIVE, SAN DIEGO CA 92121
Robert J Macdonald officer: Chief Retail Officer C/O OBALON THERAPEUTICS INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Amy Vandenberg officer: Chief Clinical & Reg Officer C/O OBALON THERAPEUTICS, INC., 5421 AVENIDA ENCINAS, SUITE F, CARLSBAD CA 92008
Nicole Vitullo 10 percent owner 3030 SCIENCE PARK ROAD, SAN DIEGO CA 92121
Brian H Dovey 10 percent owner ONE PALMER SQUARE, PRINCETON NJ 08542
Arnold L Oronsky 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022
Gilbert H Kliman 10 percent owner C/O INTERWEST PARTNERS, 467 FIRST STREET SUITE 201, LOS ALTOS CA 94022

Obalon Therapeutics (Obalon Therapeutics) Headlines

From GuruFocus